Stock listing
FULC Stock Price, News, Filings & Events — Fulcrum Therapeutics, Inc.
Selected listing: FULC · NASDAQ · USD · US
This page tracks Fulcrum Therapeutics, Inc.'s FULC:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following FULC:NASDAQ. FULC:NASDAQ is the stock-level entry point for investors researching Fulcrum Therapeutics, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Fulcrum Therapeutics, Inc. is a public company traded under the ticker FULC on the American market. The company has a market capitalization of approximately $243.2 million. Fulcrum focuses on developing innovative therapies for patients with genetically driven diseases.
- Ticker
- FULC:NASDAQ
- Asset type
- Stock
- Market cap
- $286.9M
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- NASDAQ
- Currency
- USD
Fulcrum Therapeutics, Inc. FULC:NASDAQ stock context
This page tracks Fulcrum Therapeutics, Inc.'s FULC:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following FULC:NASDAQ. FULC:NASDAQ is the stock-level entry point for investors researching Fulcrum Therapeutics, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Fulcrum Therapeutics, Inc. is a public company traded under the ticker FULC on the American market. The company has a market capitalization of approximately $243.2 million. Fulcrum focuses on developing innovative therapies for patients with genetically driven diseases.
Latest news from Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Fulcrum Therapeutics, Inc. - FULC
August 19, 2026
Fulcrum Therapeutics and Slate Medicines Announce Merger Agreement to Advance Next-Generation Migraine Therapies
August 17, 2026
Fulcrum Therapeutics Announces Discontinuation of Pociredir Program in Sickle Cell Disease and Initiation of Strategic Review
June 1, 2026
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026
April 27, 2026
Fulcrum Therapeutics Appoints Josh Lehrer to its Board of Directors
April 27, 2026
Fulcrum Therapeutics, Inc. earnings calls
Fulcrum Therapeutics, Inc. (FULC) Q1 2026 Earnings Call
April 27, 2026 · Replay with transcript and chapters
Fulcrum Therapeutics, Inc. (FULC) Q3 2025 Earnings Call
October 29, 2025 · Replay with transcript and chapters
Fulcrum Therapeutics, Inc. (FULC) Q1 2025 Earnings Call
May 1, 2025 · Replay with transcript and chapters
Fulcrum Therapeutics, Inc. (FULC) Q4 2024 Earnings Call
February 25, 2025 · Replay with transcript and chapters
Fulcrum Therapeutics, Inc. (FULC) Q3 2024 Earnings Call
November 13, 2024 · Replay with transcript and chapters
Fulcrum Therapeutics, Inc. (FULC) Q2 2024 Earnings Call
July 31, 2024 · Replay with transcript and chapters
Research Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics, Inc. investor report
Review AI stock analysis and investor report context for FULC:NASDAQ.
Fulcrum Therapeutics, Inc. company profile
View the public company page for Fulcrum Therapeutics, Inc. on 6ix.
Fulcrum Therapeutics, Inc. news
Read company news and market updates connected to Fulcrum Therapeutics, Inc..
Fulcrum Therapeutics, Inc. investor events
Find investor webinars, events, and replay context for Fulcrum Therapeutics, Inc..